<DOC>
	<DOCNO>NCT01082718</DOCNO>
	<brief_summary>Artemisinin-based combination therapy ( ACTs ) treatment choice malaria non-pregnant individual live area establish chloroquine resistance ; show safe highly efficacious . There rapidly increase experience artemisinin derivatives 2nd 3rd trimester pregnancy , 1,000 well document case report serious adverse effect mother fetus ( WHO Malaria Treatment Guidelines , 2006 ) . Many country Latin America abandon previous 1st line regimen Quinine-Clindamycin treatment malaria pregnancy , complex poorly tolerate regimen low adherence , favor ACTs , despite limited safety pharmacokinetic data use compound pregnant woman . Lack pharmacokinetic data may lead underdosing pregnant woman , subsequent reduce efficacy increase potential development resistance . One ACT regimen , Artesunate-Mefloquine , develop fixed-dose combination ( Farmanguinhos Artesunato + Mefloquina ) , part international collaborative research effort lead Drugs Neglected Diseases Initiative ( DNDi ) , manufacture Farmanguinhos , laboratory Brazilian Ministry Health . Initial clinical trial suggest well tolerate efficacious pregnant non-pregnant individual . The convenient dose afford fix drug combination make promising candidate treatment pregnant woman malaria . Preliminary pharmacokinetic data mefloquine monotherapy prophylaxis suggest peak concentration mefloquine lower pregnant woman . Prior wide-spread adoption Artesunate-Mefloquine combination , study safety , efficacy , dose optimization imperative . We propose compare pharmacokinetics fix combination mefloquine-artesunate ( MA ) treatment P.falciparum 28 pregnant woman second third trimester pharmacokinetics regimen 28 match non-pregnant P.falciparum infect woman . This allow u determine whether standard adult dose sufficient pregnant woman .</brief_summary>
	<brief_title>Pharmacokinetics Mefloquine-Artesunate Pregnant Women With Uncomplicated Plasmodium Falciparum Infection</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>1 . Cases : Pregnant woman , age ≥18 year , 2nd 3rd trimester ( gestational age ≥12 week determine LMP confirm fundal height measurement ) Controls : Nonpregnant woman ≥18 year old ( negative urine pregnancy test ) 2 . Presence P. falciparum ≤ 50,000 parasites/microliter 3 . Fever ( ≥37.5C ) history fever precede 48 hour 4 . Willing sign thumb print inform consent 5 . Willing hospitalize 3 day return schedule follow visit treatment observation delivery 6 . Willing deliver health facility 1 . Pregnancy &lt; 12 week 2 . Presence malaria specie P. falciparum slide ( P. vivax , P. malariae , P. ovale , mixed infection ( P. falciparum combination malaria specie ) 3 . History allergy hypersensitivity interventional drug 4 . Exposure antimalarial drug drug antimalarial activity within past 2 month , determine history woman . 5 . Patients take drug possible interaction study drug ( ie , digoxin warfarin ) 6 . History family history epilepsy psychiatric disorder 7 . Presence sign symptom severe malaria 8 . Inability tolerate oral medication ( repeat vomiting , impairment consciousness ) . Vomiting treatment dos lead exclusion pharmacokinetic sampling , followup drug efficacy . 9 . History chronic disease include diabetes , renal failure , hepatic failure , heart disease require antiarrhythmic drug warfarin , AIDS ( HIV exclusion , anyone AIDS HIV require HAART exclude ) , hemoglobinopathy , 10 . Participant 's inability return follow visit 11 . Age &lt; 18 year 12 . Hb &lt; 8g/dl</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Brazil</keyword>
</DOC>